Literature DB >> 29880615

Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment.

Fathima Zumla Cader1, Ron C J Schackmann2, Xihao Hu3,4, Kirsty Wienand1, Robert Redd3,4, Bjoern Chapuy1, Jing Ouyang1, Nicole Paul5, Evisa Gjini6, Mikel Lipschitz6, Philippe Armand1, David Wu7, Jonathan R Fromm7, Donna Neuberg3,4, X Shirley Liu3,4, Scott J Rodig6, Margaret A Shipp1.   

Abstract

In classical Hodgkin lymphoma (cHL), the host antitumor immune response is ineffective. Hodgkin Reed-Sternberg (HRS) cells have multifaceted mechanisms to evade the immune system, including 9p24.1/CD274(PD-L1)/PDCD1LG2(PD-L2) genetic alterations, overexpression of PD-1 ligands, and associated T-cell exhaustion and additional structural bases of aberrant antigen presentation. The clinical success of PD-1 blockade in cHL suggests that the tumor microenvironment (TME) contains reversibly exhausted T effector cells (Teffs). However, durable responses are observed in patients with β2-microglobulin/major histocompatibility complex (MHC) class I loss on HRS cells, raising the possibility of non-CD8+ T cell-mediated mechanisms of efficacy of PD-1 blockade. These observations highlight the need for a detailed analysis of the cHL TME. Using a customized time-of-flight mass cytometry panel, we simultaneously assessed cell suspensions from diagnostic cHL biopsies and control reactive lymph node/tonsil (RLNT) samples. Precise phenotyping of immune cell subsets revealed salient differences between cHLs and RLNTs. The TME in cHL is CD4+ T-cell rich, with frequent loss of MHC class I expression on HRS cells. In cHLs, we found concomitant expansion of T helper 1 (Th1)-polarized Teffs and regulatory T cells (Tregs). The cHL Th1 Tregs expressed little or no PD-1, whereas the Th1 Teffs were PD-1+ The differential PD-1 expression and likely functional Th1-polarized CD4+ Tregs and exhausted Teffs may represent complementary mechanisms of immunosuppression in cHL.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29880615      PMCID: PMC6107878          DOI: 10.1182/blood-2018-04-843714

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  58 in total

1.  Transcriptional analysis of the B cell germinal center reaction.

Authors:  Ulf Klein; Yuhai Tu; Gustavo A Stolovitzky; Jeffrey L Keller; Joseph Haddad; Vladan Miljkovic; Giorgio Cattoretti; Andrea Califano; Riccardo Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

2.  Human NK cells at early stages of differentiation produce CXCL8 and express CD161 molecule that functions as an activating receptor.

Authors:  Elisa Montaldo; Chiara Vitale; Francesca Cottalasso; Romana Conte; Timor Glatzer; Paolo Ambrosini; Lorenzo Moretta; Maria Cristina Mingari
Journal:  Blood       Date:  2012-03-07       Impact factor: 22.113

3.  Mutant MHC class II epitopes drive therapeutic immune responses to cancer.

Authors:  Sebastian Kreiter; Mathias Vormehr; Niels van de Roemer; Mustafa Diken; Martin Löwer; Jan Diekmann; Sebastian Boegel; Barbara Schrörs; Fulvia Vascotto; John C Castle; Arbel D Tadmor; Stephen P Schoenberger; Christoph Huber; Özlem Türeci; Ugur Sahin
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

4.  Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.

Authors:  Margaretha G M Roemer; Ranjana H Advani; Robert A Redd; Geraldine S Pinkus; Yasodha Natkunam; Azra H Ligon; Courtney F Connelly; Christine J Pak; Christopher D Carey; Sarah E Daadi; Bjoern Chapuy; Daphne de Jong; Richard T Hoppe; Donna S Neuberg; Margaret A Shipp; Scott J Rodig
Journal:  Cancer Immunol Res       Date:  2016-10-13       Impact factor: 11.151

5.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

6.  Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing.

Authors:  Chunhong Zheng; Liangtao Zheng; Jae-Kwang Yoo; Huahu Guo; Yuanyuan Zhang; Xinyi Guo; Boxi Kang; Ruozhen Hu; Julie Y Huang; Qiming Zhang; Zhouzerui Liu; Minghui Dong; Xueda Hu; Wenjun Ouyang; Jirun Peng; Zemin Zhang
Journal:  Cell       Date:  2017-06-15       Impact factor: 41.582

Review 7.  Regulatory T cell memory.

Authors:  Michael D Rosenblum; Sing Sing Way; Abul K Abbas
Journal:  Nat Rev Immunol       Date:  2015-12-21       Impact factor: 53.106

8.  Multiplexed ion beam imaging of human breast tumors.

Authors:  Michael Angelo; Sean C Bendall; Rachel Finck; Matthew B Hale; Chuck Hitzman; Alexander D Borowsky; Richard M Levenson; John B Lowe; Scot D Liu; Shuchun Zhao; Yasodha Natkunam; Garry P Nolan
Journal:  Nat Med       Date:  2014-03-02       Impact factor: 53.440

9.  Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo.

Authors:  Yansheng Hao; Bjoern Chapuy; Stefano Monti; Heather H Sun; Scott J Rodig; Margaret A Shipp
Journal:  Clin Cancer Res       Date:  2014-03-07       Impact factor: 12.531

10.  Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.

Authors:  Christopher D Carey; Daniel Gusenleitner; Mikel Lipschitz; Margaretha G M Roemer; Edward C Stack; Evisa Gjini; Xihao Hu; Robert Redd; Gordon J Freeman; Donna Neuberg; F Stephen Hodi; Xiaole Shirley Liu; Margaret A Shipp; Scott J Rodig
Journal:  Blood       Date:  2017-09-11       Impact factor: 22.113

View more
  52 in total

Review 1.  A Cancer Biologist's Primer on Machine Learning Applications in High-Dimensional Cytometry.

Authors:  Timothy J Keyes; Pablo Domizi; Yu-Chen Lo; Garry P Nolan; Kara L Davis
Journal:  Cytometry A       Date:  2020-06-30       Impact factor: 4.355

2.  Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58.

Authors:  Johanna Veldman; Lydia Visser; Magdalena Huberts-Kregel; Natasja Muller; Bouke Hepkema; Anke van den Berg; Arjan Diepstra
Journal:  Blood       Date:  2020-11-19       Impact factor: 22.113

3.  The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative.

Authors:  Sanjay S Patel; Jason L Weirather; Mikel Lipschitz; Ana Lako; Pei-Hsuan Chen; Gabriel K Griffin; Philippe Armand; Margaret A Shipp; Scott J Rodig
Journal:  Blood       Date:  2019-12-05       Impact factor: 22.113

4.  T-cell exhaustion correlates with improved outcomes in kidney transplant recipients.

Authors:  Miguel Fribourg; Lisa Anderson; Clara Fischman; Chiara Cantarelli; Laura Perin; Gaetano La Manna; Adeeb Rahman; Bryna E Burrell; Peter S Heeger; Paolo Cravedi
Journal:  Kidney Int       Date:  2019-02-27       Impact factor: 10.612

Review 5.  Hodgkin lymphoma.

Authors:  Joseph M Connors; Wendy Cozen; Christian Steidl; Antonino Carbone; Richard T Hoppe; Hans-Henning Flechtner; Nancy L Bartlett
Journal:  Nat Rev Dis Primers       Date:  2020-07-23       Impact factor: 52.329

6.  Fundamentals of immunology for understanding immunotherapy for lymphoma.

Authors:  Stephen M Ansell
Journal:  Blood Adv       Date:  2020-11-24

7.  Mass cytometry defines distinct immune profile in germinal center B-cell lymphomas.

Authors:  Mikael Roussel; Faustine Lhomme; Caroline E Roe; Todd Bartkowiak; Pauline Gravelle; Camille Laurent; Thierry Fest; Jonathan M Irish
Journal:  Cancer Immunol Immunother       Date:  2020-01-09       Impact factor: 6.968

8.  Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion.

Authors:  Kirsty Wienand; Bjoern Chapuy; Chip Stewart; Andrew J Dunford; David Wu; Jaegil Kim; Atanas Kamburov; Timothy R Wood; Fathima Zumla Cader; Matthew D Ducar; Aaron R Thorner; Anwesha Nag; Alexander T Heubeck; Michael J Buonopane; Robert A Redd; Kamil Bojarczuk; Lee N Lawton; Philippe Armand; Scott J Rodig; Jonathan R Fromm; Gad Getz; Margaret A Shipp
Journal:  Blood Adv       Date:  2019-12-10

9.  The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma.

Authors:  Joji Nagasaki; Yosuke Togashi; Takeaki Sugawara; Makiko Itami; Nobuhiko Yamauchi; Junichiro Yuda; Masato Sugano; Yuuki Ohara; Yosuke Minami; Hirohisa Nakamae; Masayuki Hino; Masahiro Takeuchi; Hiroyoshi Nishikawa
Journal:  Blood Adv       Date:  2020-09-08

10.  Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.

Authors:  Catherine S Diefenbach; Fangxin Hong; Richard F Ambinder; Jonathon B Cohen; Michael J Robertson; Kevin A David; Ranjana H Advani; Timothy S Fenske; Stefan K Barta; Neil D Palmisiano; Jakub Svoboda; David S Morgan; Reem Karmali; Elad Sharon; Howard Streicher; Brad S Kahl; Stephen M Ansell
Journal:  Lancet Haematol       Date:  2020-09       Impact factor: 18.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.